Clinical trials: Imaging, Diagnostic
Cognitive Decline
Flortaucipir 18F PET Imaging in BIOCARD Study
This study is designed to assess the imaging characteristics of Flortaucipir (18F-AV-1451) in subjects who participated in the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study at Johns Hopkins University.
- Trial name
- NCT03052972
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Breast Cyst, Breast Cancer Female
M5 vs. M6 Comparison Study With a Sub Study Into the Dielectric Constant of Aspirated Cyst Fluid
The MARIA breast imaging system is a Conformité Européenne (CE)-marked radio-frequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and…
- Trial name
- NCT03771833
- Testing
- MARIA scan
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Micrima, Ltd.
Alzheimer's Disease
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy.
- Trial name
- NCT00857415
- Testing
- florbetapir F 18
- Where
- 25 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Parkinson's Disease, Primary Parkinsonism
A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
The purpose of this study is to determine whether 18F-AV-133 PET scans can be used to differentiate subjects with Parkinson's Disease from other movement disorders.
- Conditions
- Parkinson's Disease, Primary Parkinsonism, Lewy Body Parkinson's Disease
- Trial name
- NCT01550484
- Testing
- 18F-AV-133
- Where
- 15 sites in United States, Australia
- Volunteers
- 170 people
- Sponsor
- Avid Radiopharmaceuticals
Endometrial Cancer, Uterine Cancer
A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping
This is a randomized, prospective, open label, multicenter study to assess the safety and utility of PINPOINT® Near Infrared Fluorescence Imaging (PINPOINT) in identification of lymph nodes (LN) in patients with uterine and…
- Conditions
- Endometrial Cancer, Uterine Cancer, Cervical Cancer
- Trial name
- FILM (NCT02209532)
- Testing
- PINPOINT
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 180 people
- Sponsor
- Novadaq Technologies ULC, now a part of Stryker
Hypertrophic Cardiomyopathy (HCM), Cardiac Imaging
ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access
This study evaluates whether healthcare providers without specialized ultrasound training can use UltraSight's machine learning based Guidance Software to perform limited transthoracic echocardiography in patients with…
- Conditions
- Hypertrophic Cardiomyopathy (HCM), Cardiac Imaging, Echocardiography, Mavacamten
- Trial name
- NCT07155434
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- UltraSight
Alzheimer Disease
A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
This study will test two different doses of florbetapir F 18 to determine which dose is best to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565330
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Prostate Cancer
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
The goal of this clinical trial is to test if the experimental agent accurately determines the aggressiveness of prostate cancer (biopsy-verified ISUP grade).
- Trial name
- uTRACE-101 (NCT06474806)
- Testing
- 64Cu-DOTA-AE105
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 168 people
- Sponsor
- Curasight
Intra-axial Tumors, Extra-axial Tumors
Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems
This is a prospective, multi-center, interventional study designed to evaluate the visualization benefits of FDA approved gadolinium-based contrast agents (GBCAs) in portable magnetic resonance imaging (pMRI) of the brain.
- Conditions
- Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions
- Trial name
- Contrast PMR (NCT07296263)
- Testing
- Portable MRI (pMRI), Gadolinium-Based Contrast Agent (GBCA)
- Where
- 6 sites in United States
- Volunteers
- 85 people
- Sponsor
- Hyperfine
Metastatic Cancer, Unresectable Solid Tumor
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
Single-center with the option to expand to multi-center, international, open label, non-randomized, multiple-dose, multi-cohort study, in participants with metastatic or unresectable cancer.
- Trial name
- NCT07057349
- Testing
- [18F]CSB-321
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cytosite Biopharma Inc.
Carcinoma, Non-small Cell Lung Cancer
Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)
This study will use imaging to look at tumor response to combination chemotherapy of gemcitabine (Gem) and cisplatin (Cis) or gemcitabine and carboplatin (Carbo) in non small cell lung cancer (NSCLC).
- Trial name
- NCT00599755
- Testing
- Comparator: CT or MRI and FDG-PET, Gemcitabine and Cisplatin or Gemcitabine and Carboplatin
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
A Non-drug Methods Study in Participants With Alzheimer's Disease
This study will investigate the volume, function and composition of the brain using magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning technology in participants with memory complaints or early signs…
- Trial name
- NCT01459016
- Testing
- PET scan using florbetapir, MRI Scan
- Where
- 16 sites in France
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Diseases
Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation
This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.
- Trial name
- NCT04535193
- Testing
- 18F-mFBG for intravenous administration
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Alzheimer's Disease
Tau Imaging in Professional Fighters
Subjects enrolled in the Professional Fighters Brain Health Study (PFBHS) will receive flortaucipir to explore its use as a biomarker for brain injury related to repetitive head trauma and to examine the relationship between…
- Trial name
- NCT02278354
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Avid Radiopharmaceuticals
Stroke, Acute Stroke
Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable MRI Device
To assess the safety and feasibility of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke, Hemorrhagic Stroke
- Trial name
- NCT07751328
- Testing
- Axana Scan and MRI
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wellumio R&D Australia Pty Ltd
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study.
- Trial name
- JADE EXTEND (NCT03422822)
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 539 sites in United States, Argentina and 26 more
- Volunteers
- 3,166 people
- Sponsor
- Pfizer
Buccal Mucosa Cancer, Gingival Cancer
Role of Imaging to Predict the Deep Surgical Margin in Gingivobuccal Complex Tumors
In gingivobuccal complex tumors, the skin margin is assessed by palpation (skin pinch test). There is no objective method of assessment of skin margin.
- Trial name
- NCT03137953
- Testing
- Clinical Evaluation, Radiological Imaging
- Where
- India
- Volunteers
- 30 people
- Sponsor
- HealthCare Global Enterprise Ltd.
High-Grade Glioma (WHO III-IV), Cerebral Vascular Conditions Requiring Surgical Intervention
Evaluation of Image Quality and Safety of the MyVeo Surgical Visualization Headset During Standard Neurosurgical and Reconstructive Procedures Using Compatible Microscopes.
This study looks at how well the MyVeo surgical visualization headset works during routine surgeries. MyVeo is a wearable device that helps surgeons see the surgical area in high detail, including blood flow and tissue…
- Conditions
- High-Grade Glioma (WHO III-IV), Cerebral Vascular Conditions Requiring Surgical Intervention, Conditions Requiring Plastic and Reconstructive Surgery
- Trial name
- IMED-MYVEO (NCT07164053)
- Testing
- MyVeo is an all-in-one surgical visualization headset used with compatible surgical microscopes and other medical imaging systems in the area of neurosurgery, ENT, spine, plastic and reconstructive su
- Sponsor
- Leica Microsystems (Schweiz) AG
Contrast Enhancement in Magnetic Resonance Imaging, Healthy Volunteers
A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants
The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Chinese healthy male participants: the safety of BAY1747846 when given at increasing single doses…
- Trial name
- NCT06135181
- Testing
- Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg, Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Pancreatic Cancer
Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2*…
- Trial name
- NCT06129422
- Testing
- NMK89
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Nihon Medi-Physics Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.